This finding could be related to the fact that whole exome sequencing was used, which may lead to an underestimation of these LOH-based scores or may reflect a less stringent correlation between signature AC3, “BRCAness” and LST/HRD scores in RCC in comparison to breast or ovarian cancer with germline BRCA1/2 mutations. This evidence concerns the gene BRCA1 and renal cell carcinoma.